Dow Today: Pfizer (PFE) Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Dow Jones Industrial Average ( ^DJI) is trading up 56 points (+0.3%) at 16,277 as of Monday, Dec 23, 2013, 1:35 p.m. ET. During this time, 160 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 372.4 million. The NYSE advances/declines ratio sits at 2,214 issues advancing vs. 823 declining with 100 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

The Dow component leading the way higher looks to be Pfizer (NYSE: PFE), which is sporting a 16-cent gain (+0.6%) bringing the stock to $30.42. This single gain is lifting the Dow Jones Industrial Average by 1.21 points or roughly accounting for 2.2% of the Dow's overall gain. Volume for Pfizer currently sits at 13.5 million shares traded vs. an average daily trading volume of 25.6 million shares.

Pfizer has a market cap of $199.03 billion and is part of the health care sector and drugs industry. Shares are up 22.4% year to date as of Friday's close. The stock's dividend yield sits at 3.4%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. The company has a P/E ratio of 20.3, above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign